BioCryst Pharmaceuticals, Inc.
BCRX
$6.84
-$0.495-6.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 131.53M | 117.09M | 109.33M | 92.76M | 93.40M |
| Total Other Revenue | -- | -- | -- | -- | 2.52M |
| Total Revenue | 131.53M | 117.09M | 109.33M | 92.76M | 93.40M |
| Cost of Revenue | 55.57M | 44.31M | 39.36M | 47.89M | 67.12M |
| Gross Profit | 75.96M | 72.78M | 69.98M | 44.88M | 26.29M |
| SG&A Expenses | 80.47M | 65.08M | 61.21M | 59.36M | 64.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.04M | 109.39M | 100.57M | 107.25M | 131.14M |
| Operating Income | -4.51M | 7.69M | 8.76M | -14.49M | -37.74M |
| Income Before Tax | -25.99M | -13.45M | -12.50M | -35.01M | -63.16M |
| Income Tax Expenses | 804.00K | 586.00K | 172.00K | 365.00K | -1.43M |
| Earnings from Continuing Operations | -26.80M | -14.03M | -12.67M | -35.38M | -61.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.80M | -14.03M | -12.67M | -35.38M | -61.73M |
| EBIT | -4.51M | 7.69M | 8.76M | -14.49M | -37.74M |
| EBITDA | -2.43M | 8.00M | 9.08M | -14.18M | -36.11M |
| EPS Basic | -0.13 | -0.07 | -0.06 | -0.17 | -0.31 |
| Normalized Basic EPS | -0.08 | -0.04 | -0.04 | -0.11 | -0.18 |
| EPS Diluted | -0.13 | -0.07 | -0.06 | -0.17 | -0.31 |
| Normalized Diluted EPS | -0.08 | -0.04 | -0.04 | -0.11 | -0.18 |
| Average Basic Shares Outstanding | 207.38M | 206.91M | 206.43M | 206.06M | 201.41M |
| Average Diluted Shares Outstanding | 207.38M | 206.91M | 206.43M | 206.06M | 201.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
